Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310006, P. R. China.
National Health Commission Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, Zhejiang, 310003, P. R. China.
Cancer Commun (Lond). 2020 Dec;40(12):681-693. doi: 10.1002/cac2.12115. Epub 2020 Dec 8.
Hepatocellular carcinoma (HCC) is one of the most prevalent and fatal digestive tumors. Treatment for this disease has been constraint by heterogeneity of this group of tumors, which has greatly limited the progress in personalized therapy. Although existing studies have revealed the genetic and epigenetic blueprints that drive HCCs, many of the molecular mechanisms that lead to HCCs remain elusive. Recent advances in techniques for studying functional genomics, such as genome sequencing and transcriptomic analyses, have led to the discovery of molecular mechanisms that participate in the initiation and evolution of HCC. Integrative multi-omics analyses have identified several molecular subtypes of HCC associated with specific molecular characteristics and clinical outcomes. Deciphering similar molecular features among highly heterogeneous HCC patients is a prerequisite to implementation of personalized therapeutics. This review summarizes the current research progresses in precision therapy on the backbone of molecular subtypes of HCC.
肝细胞癌（HCC）是最常见和致命的消化系统肿瘤之一。由于该组肿瘤的异质性，治疗受到限制，这极大地限制了个性化治疗的进展。尽管现有研究揭示了驱动 HCC 的遗传和表观遗传蓝图，但导致 HCC 的许多分子机制仍难以捉摸。最近在研究功能基因组学技术方面的进展，如基因组测序和转录组分析，导致发现了参与 HCC 发生和演变的分子机制。综合多组学分析已经确定了几种与特定分子特征和临床结果相关的 HCC 分子亚型。在高度异质性的 HCC 患者中破译类似的分子特征是实施个性化治疗的前提。本综述总结了基于 HCC 分子亚型的精准治疗的最新研究进展。
